Amyotrophic lateral sclerosis ALS Market Size, Industry Trends, and Statistics Report

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast 2028

Report ID: MIReports 6677 | Number of pages: 102 | Publish Date: Jun 2019 | Category: Lifesciences and Healthcare 
Report Summary

"Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering:
United States
EU5 (Germany, France, Italy, Spain and the United Kingdom) 
Japan 

Study Period: 2016-2028

Amyotrophic lateral sclerosis (ALS) Understanding and Treatment Algorithm
The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Amyotrophic lateral sclerosis (ALS)in the US, Europe, and Japan are also provided in the report.

Amyotrophic lateral sclerosis (ALS) Epidemiology
This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Amyotrophic lateral sclerosis (ALS) Product Profiles & Analysis
This part of the Amyotrophic lateral sclerosis (ALS) report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Amyotrophic lateral sclerosis (ALS) Market Outlook
The Amyotrophic lateral sclerosis (ALS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Amyotrophic lateral sclerosis (ALS) Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Amyotrophic lateral sclerosis (ALS) Report Insights
Patient Population in Amyotrophic lateral sclerosis (ALS)
Therapeutic Approaches in Amyotrophic lateral sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) Pipeline Analysis
Amyotrophic lateral sclerosis (ALS) Market Size and Trends
Amyotrophic lateral sclerosis (ALS) Market Opportunities
Impact of upcoming Therapies in Amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) Report Key Strengths
10 Year Forecast 
7MM Coverage 
Epidemiology Segmentation 
Drugs Uptake 
Highly Analyzed Market 
Key Cross Competition 

Amyotrophic lateral sclerosis (ALS) Report Assessment 
Current Treatment Practices in Amyotrophic lateral sclerosis (ALS)
Unmet Needs in Amyotrophic lateral sclerosis (ALS)
Detailed Amyotrophic lateral sclerosis (ALS) Pipeline Product Profiles 
Market Attractiveness 
Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Amyotrophic lateral sclerosis (ALS) market
Organize sales and marketing efforts by identifying the best opportunities for Amyotrophic lateral sclerosis (ALS) market
To understand the future market competition in the Amyotrophic lateral sclerosis (ALS) market.

Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.
Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Interested in this report?
Get your sample now!
Download Sample 
Table of Contents
1 Key Insights
2 Amyotrophic lateral sclerosis (ALS) Market Overview at a Glance
    2.1 Market Share (%) Distribution of Amyotrophic lateral sclerosis (ALS) in 2018
    2.2 Market Share (%) Distribution of Amyotrophic lateral sclerosis (ALS) in 2028
3 Amyotrophic lateral sclerosis (ALS): Disease Background and Overview
    3.1 Introduction
    3.2 Symptoms
    3.3 Etiology
    3.4 Risk Factor
    3.5 Pathophysiology
    3.6 Diagnosis
    3.7 Treatment
4 Epidemiology and Patient Population
    4.1. Key Findings
    4.2. Total Prevalent/ Incident Patient Population of Amyotrophic lateral sclerosis (ALS) in 7MM
    4.3. Total Prevalent Patient Population of Amyotrophic lateral sclerosis (ALS) in 7MM – By Countries
5 Epidemiology of Amyotrophic lateral sclerosis (ALS) by Countries (2016-2028)
    5.1 United States- Epidemiology (2016-2028)
        5.1.1 Assumptions and Rationale
        5.1.2 Prevalent/Incident Cases of Amyotrophic lateral sclerosis (ALS) in the United States
        5.1.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the United States
        5.1.4 Sex- Specific Cases of Amyotrophic lateral sclerosis (ALS) in the United States
        5.1.5 Diagnosed Cases of Amyotrophic lateral sclerosis (ALS) in the United States
        5.1.6 Treatable Cases of Amyotrophic lateral sclerosis (ALS) in the United States
    5.2 EU5 Countries
        5.2.1 Germany
            5.2.1.1 Assumptions and Rationale
            5.2.1.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the Germany
            5.2.1.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the Germany
            5.2.1.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the Germany
            5.2.1.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the Germany
            5.2.1.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
        5.2.2 France
            5.2.2.1 Assumptions and Rationale
            5.2.2.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the France
            5.2.2.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the France
            5.2.2.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the France
            5.2.2.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the France
            5.2.2.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
        5.2.3 Italy
            5.2.3.1 Assumptions and Rationale
            5.2.3.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the Italy
            5.2.3.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the Italy
            5.2.3.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the Italy
            5.2.3.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the Italy
            5.2.3.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
        5.2.4 Spain
            5.2.4.1 Assumptions and Rationale
            5.2.4.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the Spain
            5.2.4.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the Spain
            5.2.4.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the Spain
            5.2.4.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the Spain
            5.2.4.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
        5.2.5 United Kingdom
            5.2.5.1 Assumptions and Rationale
            5.2.5.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the United Kingdom
            5.2.5.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the United Kingdom
            5.2.5.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the United Kingdom
            5.2.5.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the United Kingdom
            5.2.5.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
    5.3 Japan
        5.3.1 Assumptions and Rationale
        5.3.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the Japan
        5.3.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the Japan
        5.3.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the Japan
        5.3.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the Japan
        5.3.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
6 Current Treatment & Medical practices
6.1 Treatment Algorithm
6.2 Treatment Guidelines
7 Unmet Needs
8 Marketed Product
    8.1 Drug A: Company 1
        8.1.1 Drug Description
        8.1.2 Mechanism of Action
        8.1.3 Clinical Trials Details
        8.1.4 Advantages & Disadvantages
        8.1.5 Safety and Efficacy
        8.1.6 Product Profile
    8.2 Drug B: Company 2
        8.2.1 Drug Description
        8.2.2 Mechanism of Action
        8.2.3 Clinical Trials Details
        8.2.4 Advantages & Disadvantages
        8.2.5 Safety and Efficacy
        8.2.6 Product Profile
    8.3 Drug C: Company 3
        8.3.1 Drug Description
        8.3.2 Mechanism of Action
        8.3.3 Clinical Trials Details
        8.3.4 Advantages & Disadvantages
        8.3.5 Safety and Efficacy
        8.3.6 Product Profile
    8.4 Drug D: Company 4
        8.4.1 Drug Description
        8.4.2 Mechanism of Action
        8.4.3 Clinical Trials Details
        8.4.4 Advantages & Disadvantages
        8.4.5 Safety and Efficacy
        8.4.6 Product Profile
    8.5 Drug E: Company 5
        8.5.1 Drug Description
        8.5.2 Mechanism of Action
        8.5.3 Clinical Trials Details
        8.5.4 Advantages & Disadvantages
        8.5.5 Safety and Efficacy
        8.5.6 Product Profile
    8.6 : Company 6
        8.6.1 Drug Description
        8.6.2 Mechanism of Action
        8.6.3 Clinical Trials Details
        8.6.4 Advantages & Disadvantages
        8.6.5 Safety and Efficacy
        8.6.6 Product Profile
    8.7 : Company 7
        8.7.1 Drug Description
        8.7.2 Mechanism of Action
        8.7.3 Clinical Trials Details
        8.7.4 Advantages & Disadvantages
        8.7.5 Safety and Efficacy
        8.7.6 Product Profile
    8.8 : Company 8
        8.8.1 Drug Description
        8.8.2 Mechanism of Action
        8.8.3 Clinical Trials Details
        8.8.4 Advantages & Disadvantages
        8.8.5 Safety and Efficacy
        8.8.6 Product Profile
9 Emerging Drugs
    9.1 Key Cross Competition
    9.2 Emerging company
        9.2.1 Emerging Drug A: Company 1
            9.2.1.1 Other Development Activities
            9.2.1.2 Clinical Development
            9.2.1.3 Clinical Trials Information
            9.2.1.4 Safety and Efficacy
            9.2.1.5 Advantages and Disadvantages
            9.2.1.6 Product Profile
        9.2.2 Emerging Drug B: Company 2
            9.2.2.1 Other Development Activities
            9.2.2.2 Clinical Development
            9.2.2.3 Clinical Trials Information
            9.2.2.4 Safety and Efficacy
            9.2.2.5 Advantages and Disadvantages
            9.2.2.6 Product Profile
        9.2.3 Emerging Drug C: Company 3
            9.2.3.1 Other Development Activities
            9.2.3.2 Clinical Development
            9.2.3.3 Clinical Trials Information
            9.2.3.4 Safety and Efficacy
            9.2.3.5 Advantages and Disadvantages
            9.2.3.6 Product Profile
        9.2.4 Emerging Drug D: Company 4
            9.2.4.1 Other Development Activities
            9.2.4.2 Clinical Development
            9.2.4.3 Clinical Trials Information
            9.2.4.4 Safety and Efficacy
            9.2.4.5 Advantages and Disadvantages
            9.2.4.6 Product Profile
        9.2.5 Emerging Drug E: Company 5
            9.2.5.1 Other Development Activities
            9.2.5.2 Clinical Development
            9.2.5.3 Clinical Trials Information
            9.2.5.4 Safety and Efficacy
            9.2.5.5 Advantages and Disadvantages
            9.2.5.6 Product Profile
10 7MM Market Analysis
    10.1 7MM Market Size of Amyotrophic lateral sclerosis (ALS)
    10.2 7MM Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS)
    10.3 7MM Market Sales of Amyotrophic lateral sclerosis (ALS) by Products
11 The United States Market Outlook
    11.1 Market Size of Amyotrophic lateral sclerosis (ALS) in United States
    11.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in United States
    11.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in United States
    11.4 Analysis of Upcoming Therapies and Impact on the Market
12 EU5 Countries Market Outlook
    12.1 Market Size of Amyotrophic lateral sclerosis (ALS) in EU5
    12.2 Market Size of Amyotrophic lateral sclerosis (ALS) in Germany
        12.2.1 Market Size of Amyotrophic lateral sclerosis (ALS) in Germany
        12.2.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in Germany
        12.2.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Germany
        12.2.4 Analysis of Upcoming Therapies and Impact on the Market
    12.3 Market Size of Amyotrophic lateral sclerosis (ALS) in France
        12.3.1 Market Size of Amyotrophic lateral sclerosis (ALS) in France
        12.3.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in France
        12.3.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in France
        12.3.4 Analysis of Upcoming Therapies and Impact on the Market
    12.4 Market Size of Amyotrophic lateral sclerosis (ALS) in Italy
        12.4.1 Market Size of Amyotrophic lateral sclerosis (ALS) in Italy
        12.4.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in Italy
        12.4.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Italy
        12.4.4 Analysis of Upcoming Therapies and Impact on the Market
    12.5 Market Size of Amyotrophic lateral sclerosis (ALS) in Spain
        12.5.1 Market Size of Amyotrophic lateral sclerosis (ALS) in Spain
        12.5.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in Spain
        12.5.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Spain
        12.5.4 Analysis of Upcoming Therapies and Impact on the Market
    12.6 Market Size of Amyotrophic lateral sclerosis (ALS) in United Kingdom
        12.6.1 Market Size of Amyotrophic lateral sclerosis (ALS) in United Kingdom
        12.6.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in United Kingdom
        12.6.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in United Kingdom
        12.6.4 Analysis of Upcoming Therapies and Impact on the Market
13 The Japan Market Outlook
    13.1 Market Size of Amyotrophic lateral sclerosis (ALS) in Japan
    13.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in Japan
    13.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Japan
    13.4 Analysis of Upcoming Therapies and Impact on the Market
14 Cost Analysis of Amyotrophic lateral sclerosis (ALS)
15 Generic Competition in Amyotrophic lateral sclerosis (ALS) Market
16 Market Drivers
17 Market Barriers
18 Report Methodology
    18.1 Methodology/Research Approach
    18.2 Data Source
        18.2.1 Secondary Sources
        18.2.2 Primary Sources


List of Figures
    Figure Market Share (%) Distribution of Amyotrophic lateral sclerosis (ALS) in 2019
    Figure Market Share (%) Distribution of Amyotrophic lateral sclerosis (ALS) in 2028
    Figure Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM
    Figure Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM
    Figure Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)
    Figure Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)
    Figure Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)
    Figure Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)
    Figure Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)
    Figure Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028)
    Figure Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028)
    Figure Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028)
    Figure Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028)
    Figure Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028)
    Figure Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028)
    Figure Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028)
    Figure Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028)
    Figure Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028)
    Figure Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028)
    Figure Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028)
    Figure Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028)
    Figure Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028)
    Figure Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028)
    Figure Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028)
    Figure Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028)
    Figure Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028)
    Figure Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028)
    Figure Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028)
    Figure Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028)
    Figure Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in United Kingdom (2016-2028)
    Figure Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in United Kingdom (2016-2028)
    Figure Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in United Kingdom (2016-2028)
    Figure Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in United Kingdom (2016-2028)
    Figure Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in United Kingdom (2016-2028)
    Figure Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028)
    Figure Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028)
    Figure Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028)
    Figure Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028)
    Figure Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028)
    Figure Treatment algorithm for Amyotrophic lateral sclerosis (ALS)
    Figure Diagnosis and Therapy selection
    Figure Unmet Needs of Amyotrophic lateral sclerosis (ALS) Disease
    Figure 7MM- Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028)
    Figure 7MM- Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028)
    Figure US Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2016-2028)
    Figure United States-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028)
    Figure United States-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2017-2028)
    Figure EU5 Market Size of Amyotrophic lateral sclerosis (ALS) (MS) in USD, Million (2016-2028)
    Figure Germany Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2016-2028)
    Figure Germany -Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028)
    Figure Germany -Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2017-2028)
    Figure France Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2016-2028)
    Figure France -Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028)
    Figure France -Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2017-2028)
    Figure Italy Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2016-2028)
    Figure Italy -Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028)
    Figure Italy -Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2017-2028)
    Figure Spain Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2016-2028)
    Figure Spain -Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028)
    Figure Spain -Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2017-2028)
    Figure United Kingdom Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2016-2028)
    Figure United Kingdom -Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028)
    Figure United Kingdom -Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2017-2028)
    Figure Japan Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2016-2028)
    Figure Japan -Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028)